Usefulness of Proton and Phosphorus MR Spectroscopic Imaging for Early Diagnosis of Parkinson's Disease

Journal of Neuroimaging

Volumn 25, Issue 1, 2015, Pages 105-110

  Weiduschat, Nora ^a   Mao, Xiangling ^a   Beal, M Flint ^a   Nirenberg, Melissa J ^b   Shungu, Dikoma C ^a   Henchcliffe, Claire ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Diagnosis; Magnetic resonance spectroscopy; Mitochondrial dysfunction; Parkinson's disease

Indexed keywords

ADENOSINE TRIPHOSPHATE; CHOLINE; CREATINE; LACTIC ACID; N ACETYLASPARTIC ACID; PHOSPHORUS; PROTON; ASPARTIC ACID; BIOLOGICAL MARKER; N-ACETYLASPARTATE;

ADULT; ANAEROBIC GLYCOLYSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE DURATION; EARLY DIAGNOSIS; ENERGY METABOLISM; HUMAN; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE PHOSPHORYLATION; PARKINSON DISEASE; UNIFIED PARKINSON DISEASE RATING SCALE; ANALOGS AND DERIVATIVES; DIAGNOSTIC USE; FEMALE; MALE; METABOLISM; PROCEDURES; PROTON NUCLEAR MAGNETIC RESONANCE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ASPARTIC ACID; BIOLOGICAL MARKERS; CHOLINE; CREATINE; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PHOSPHORUS; PROTON MAGNETIC RESONANCE SPECTROSCOPY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84920945580     PISSN: 10512284     EISSN: 15526569     Source Type: Journal    
DOI: 10.1111/jon.12074     Document Type: Article

References (30)

1. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
2. Bindoff L, Birch-Machin M, Cartlidge N, et al. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease. J Neurol Sci 1991;104:203-208.
3. Yoshino H, Nakagawa-Hattori Y, Kondo T, et al. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J Neural Trans Parkinson Dis Dement Sect 1992;4:27-34.
4. Keeney P, Xie J, Capaldi R, et al. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci 2006;26:5256-5264.
5. Hyun D, Lee M, Hattori N, et al. Effect of wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome. J Biol Chem 2002;277:28572-28577.
6. Palacino J, Sagi D, Goldberg M, et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 2004;279:18614-18622.
7. Beal MF. Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2009;15(Suppl 3):S189-194.
8. Cooper O, Seo H, Andrabi S, et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med 2012;4:141ra90.
9. Henchcliffe C, Shungu D, Mao X, et al. Multinuclear magnetic resonance spectroscopy for in vivo assessment of mitochondrial dysfunction in Parkinson's disease. Ann N Y Acad Sci 2008;1147:206-220.
10. Hattingen E, Magerkurth J, Pilatus U, et al. Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. Brain 2009;132:3285-3297.
11. Brockmann K, Hilker R, Pilatus U, et al. GBA-associated PD. Neurodegeneration, altered membrane metabolism, and lack of energy failure. Neurology 2012;79:213-220.
12. Hu M, Taylor-Robinson S, Chaudhuri K, et al. Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. Brain 2000;123 (Pt 2):340-352.
13. Barbiroli B, Martinelli P, Patuelli A, et al. Phosphorus magnetic resonance spectroscopy in multiple system atrophy and Parkinson's disease. Mov Disord 1999;14:430-435.
14. Bowen BC, Block RE, Sanchez-Ramos J, et al. Proton MR spectroscopy of the brain in 14 patients with Parkinson disease. AJNR Am J Neuroradiol 1995;16:61-68.
15. O'Neill J, Schuff N, Marks WJ, et al. Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease. Mov Disord 2002;17:917-927.
16. Guevara CA, Blain CR, Stahl D, et al. Quantitative magnetic resonance spectroscopic imaging in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. Eur J Neurol 2010;17:1193-1202.
17. Emir UE, Tuite PJ, Öz G. Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 tesla proton MRS. PLoS One 2012;7:e30918.
18. Rango M, Bonifati C, Bresolin N. Parkinson's disease and brain mitochondrial dysfunction: a functional phosphorus magnetic resonance spectroscopy study. J Cereb Blood Flow Metab 2006;26:283-290.
19. Hoehn M, Yahr M. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
20. Fahn S, Elton R, UPDRS program members. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden C, Goldstein M, Calne D, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan Healthcare Information; 1987:153-163.
21. Duyn JH, Gillen J, Sobering G, et al. Multisection proton MR spectroscopic imaging of the brain. Radiology 1993;188:277-282.
22. Kaufmann P, Shungu DC, Sano MC, et al. Cerebral lactic acidosis correlates with neurological impairment in MELAS. Neurology 2004;62:1297-1302.
23. Mathew SJ, Mao X, Keegan KA, et al. Ventricular cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with generalized anxiety disorder: an in vivo 3.0 T (1)H MRS imaging study. NMR Biomed 2009;22:251-258.
24. Hoang TQ, Bluml S, Dubowitz DJ, et al. Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's diseases. Neurology 1998;50:1033-1040.
25. Abe K, Terakawa H, Takanashi M, et al. Proton magnetic resonance spectroscopy of patients with Parkinsonism. Brain Res Bull 2000;52:589-595.
26. Clarke CE, Lowry M. Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy. Eur J Neurol 2000;7:661-665.
27. Tedeschi G, Litvan I, Bonavita S, et al. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. Brain 1997;120(Pt 9):1541-1552.
28. Griffith HR, den Hollander JA, Okonkwo OC, et al. Brain N-acetylaspartate is reduced in Parkinson disease with dementia. Alzheimer Dis Assoc Disord 2008;22:54-60.
29. Gröger A, Chadzynski G, Godau J, et al. Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson's disease. Eur Radiol 2011;21:1962-1969.
30. Camicioli RM, Korzan JR, Foster SL, et al. Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia. Neurosci Lett 2004;354:177-180.